Literature DB >> 18404783

Chemotherapy and cerebrovascular disease.

M Saynak1, R Cosar-Alas, V Yurut-Caloglu, M Caloglu, Z Kocak, C Uzal.   

Abstract

Cerebrovascular disease is common in cancer patients. Some tumors are at high risk for cerebrovascular complications. The development of cerebrovascular disease may be provoked by cancer treatment. No well-planned prospective studies about other causes of thrombosis are available, although various case reports about thrombosis related to chemotherapy have been published. L-asparaginase, cisplatin, 5-fluorouracil (5-FU) and methotrexate are anticancer agents which are reported to relate to stroke. The mechanisms by which antineoplastic agents may lead to stroke include endothelium toxicity and abnormalities of coagulation factors. Also, brain hemorrhages that could result from chemotherapy effects on the hemostatic system were reported. Besides, it is difficult to determine whether stroke is caused by chemotherapy or cancer itself. Clinicians deal not only with problems originating from cancer itself, but also with the complications resulting from its treatment. Treatment-induced cerebrovascular disorders affect quality of life and survival in cancer patients. For this reason, cancer treatment should be planned by taking into consideration the possibility of cerebrovascular complications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18404783

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  8 in total

Review 1.  Late effects of cancer treatment: consequences for long-term brain cancer survivors.

Authors:  Montse Alemany; Roser Velasco; Marta Simó; Jordi Bruna
Journal:  Neurooncol Pract       Date:  2020-07-16

Review 2.  Cancer and Cerebrovascular Disease.

Authors:  Harold P Adams
Journal:  Curr Neurol Neurosci Rep       Date:  2019-08-23       Impact factor: 5.081

Review 3.  Cardiovascular Disease in Adult Cancer Survivors: a Review of Current Evidence, Strategies for Prevention and Management, and Future Directions for Cardio-oncology.

Authors:  Jaidyn Muhandiramge; John R Zalcberg; G J van Londen; Erica T Warner; Prudence R Carr; Andrew Haydon; Suzanne G Orchard
Journal:  Curr Oncol Rep       Date:  2022-07-07       Impact factor: 5.075

4.  Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor.

Authors:  Yukio Sassa; Yasuaki Hata
Journal:  Clin Ophthalmol       Date:  2010-04-26

5.  Occult breast cancer presenting as metastatic adenocarcinoma of unknown primary: clinical presentation, immunohistochemistry, and molecular analysis.

Authors:  Jue Wang; Geoffrey Talmon; Jordan H Hankins; Charles Enke
Journal:  Case Rep Oncol       Date:  2012-01-07

6.  Factors leading to the risk of stroke mortality: a cross-sectional study with lung cancer patient-based large sample.

Authors:  Lei Chen; Xinmin Zhao; Sheng Wang
Journal:  Eur J Cancer Prev       Date:  2022-01-01       Impact factor: 2.164

7.  Clinical Features and Prognostic Factors of Acute Ischemic Stroke Related to Malignant Gastrointestinal Tumor.

Authors:  Yating Liu; Xin Li; Feixue Song; Xin Yan; Zhijian Han; Futian Tang; Yumin Li
Journal:  Front Neurol       Date:  2021-11-25       Impact factor: 4.003

8.  Serum Alkaline Phosphatase in Cryptogenic Stroke Cases with Active Cancer.

Authors:  Tesseki Izumi; Hitoki Nanaura; Naohiko Iguchi; Maki Ozaki; Kazuma Sugie
Journal:  Intern Med       Date:  2022-03-01       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.